Chemotherapy induced right ventricular cardiomyopathy; a systematic review and meta-analysis.
anthracycline
breast cancer
cardiomyopathy
cardiooncology
chemotherapy
right ventri cular dysfunction
trastuzumab
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
21
11
2022
accepted:
29
06
2023
medline:
21
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
Left ventricular dysfunction and cardiomyopathy are well documented adverse effects associated with chemotherapy agents. Limited information exists regarding the impact of chemotherapeutic agents on the integrity and function of the right ventricle (RV). The current metanalysis compared pre- chemotherapy versus post- chemotherapy RV parameters measured on 2D echocardiography in patients receiving anthracycline and/or trastuzumab across all breast cancer patients. A systematic search across PubMed, EMBASE and Cochrane databases were performed from inception of the databases until November 2021 for relevant studies. We used the inverse variance method with a random effect model and DerSimonian and Laird method of Tau2 generation to calculate mean difference [MD] with 95% confidence interval [CI]. The analysis was carried out using RevMan Version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). Fifteen studies, constituting total of 644 patients, met the inclusion criteria, with most studies having a follow up period of less than 12 months from initiation of chemotherapy. Anthracycline and/or Trastuzumab chemotherapy resulted in a statistically significant reduction in right ventricular ejection fraction (RVEF) at follow-up [MD: 2.70, 95% CI: 0.27 to 5.13, Chemotherapy with anthracyclines and trastuzumab negatively affects right ventricular function leading to decline in RVEF, RVFAC, RVFWLS and LVEF.
Sections du résumé
Background
UNASSIGNED
Left ventricular dysfunction and cardiomyopathy are well documented adverse effects associated with chemotherapy agents. Limited information exists regarding the impact of chemotherapeutic agents on the integrity and function of the right ventricle (RV).
Objectives
UNASSIGNED
The current metanalysis compared pre- chemotherapy versus post- chemotherapy RV parameters measured on 2D echocardiography in patients receiving anthracycline and/or trastuzumab across all breast cancer patients.
Methods
UNASSIGNED
A systematic search across PubMed, EMBASE and Cochrane databases were performed from inception of the databases until November 2021 for relevant studies. We used the inverse variance method with a random effect model and DerSimonian and Laird method of Tau2 generation to calculate mean difference [MD] with 95% confidence interval [CI]. The analysis was carried out using RevMan Version 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).
Results
UNASSIGNED
Fifteen studies, constituting total of 644 patients, met the inclusion criteria, with most studies having a follow up period of less than 12 months from initiation of chemotherapy. Anthracycline and/or Trastuzumab chemotherapy resulted in a statistically significant reduction in right ventricular ejection fraction (RVEF) at follow-up [MD: 2.70, 95% CI: 0.27 to 5.13,
Conclusions
UNASSIGNED
Chemotherapy with anthracyclines and trastuzumab negatively affects right ventricular function leading to decline in RVEF, RVFAC, RVFWLS and LVEF.
Identifiants
pubmed: 37600030
doi: 10.3389/fcvm.2023.1103941
pmc: PMC10434797
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1103941Informations de copyright
© 2023 Theetha Kariyanna, Kumar, Jayarangaiah, Shetty, Chowdhury, Das and Jayarangaiah.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cardiol J. 2016;23(3):270-80
pubmed: 27173679
Clin Res Cardiol. 2012 Jun;101(6):415-26
pubmed: 22249492
J Am Coll Cardiol. 2014 Jan 28;63(3):240-8
pubmed: 24161324
Eur J Echocardiogr. 2011 Nov;12(11):834-40
pubmed: 21880609
Cancer. 2002 Oct 1;95(7):1592-600
pubmed: 12237930
JACC CardioOncol. 2021 Mar 16;3(1):1-16
pubmed: 34396303
Eur J Nucl Med. 1988;13(11):563-7
pubmed: 3162416
J Clin Oncol. 2005 Nov 1;23(31):7820-6
pubmed: 16258084
Cancer Chemother Pharmacol. 1989;23(2):101-4
pubmed: 2910506
J Clin Oncol. 2007 Sep 1;25(25):3991-4008
pubmed: 17577017
Echo Res Pract. 2016 Sep;3(3):79-84
pubmed: 27457966
Clin Cardiol. 2017 Jul;40(7):437-443
pubmed: 28191909
J Clin Oncol. 2004 Jan 15;22(2):322-9
pubmed: 14722042
Eur J Pharmacol. 2020 Jan 5;866:172818
pubmed: 31758940
Circulation. 2017 Sep 5;136(10):e172-e194
pubmed: 28784624
Int J Cardiol. 2013 Oct 15;168(6):5465-7
pubmed: 24090744
Cancer Treat Rep. 1978 Jun;62(6):857-64
pubmed: 667859
J Clin Oncol. 2005 May 1;23(13):2900-2
pubmed: 15860848
Cancer. 1967 Mar;20(3):333-53
pubmed: 4290058
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Acta Cardiol Sin. 2016 Sep;32(5):550-559
pubmed: 27713603
J Oncol. 2015;2015:609194
pubmed: 26339242
J Adv Pract Oncol. 2018 Mar;9(2):160-176
pubmed: 30588351
Adv Ther. 2009 Jul;26 Suppl 1:S9-17
pubmed: 19669637
J Am Coll Cardiol. 1995 Mar 15;25(4):937-42
pubmed: 7884101
Eur J Heart Fail. 2019 Apr;21(4):529-535
pubmed: 30811091
BMC Med Res Methodol. 2005 Apr 20;5:13
pubmed: 15840177
J Cardiovasc Magn Reson. 2017 Apr 10;19(1):44
pubmed: 28395671
Circulation. 2012 Oct 2;126(14):1681-8
pubmed: 22932258
Oxid Med Cell Longev. 2010 May-Jun;3(3):168-77
pubmed: 20716941
J Nucl Cardiol. 2016 Feb;23(1):87-97
pubmed: 26338424
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
Clin Med Insights Cardiol. 2019 Jul 29;13:1179546819866445
pubmed: 31384135
Curr Oncol Rep. 2016 Mar;18(3):15
pubmed: 26838585
J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8
pubmed: 20620859
BMC Cancer. 2018 Oct 25;18(1):1037
pubmed: 30359235
J Am Soc Echocardiogr. 2015 Nov;28(11):1329-38
pubmed: 26296986
N Engl J Med. 1998 Sep 24;339(13):900-5
pubmed: 9744975
Future Cardiol. 2018 May;14(3):197-201
pubmed: 29355045
Eur J Nucl Med. 1996 May;23(5):511-6
pubmed: 8698054
Echocardiography. 2016 Mar;33(3):406-15
pubmed: 26498324
J Am Soc Echocardiogr. 2014 Sep;27(9):911-39
pubmed: 25172399
Postgrad Med J. 2017 May;93(1099):271-274
pubmed: 27651497
J Am Soc Echocardiogr. 2014 May;27(5):568-79
pubmed: 24534652
Eur Heart J Cardiovasc Imaging. 2014 Oct;15(10):1063-93
pubmed: 25239940
Echocardiography. 2016 Jul;33(7):992-1000
pubmed: 26864642
Eur Heart J. 2000 Aug;21(16):1387-96
pubmed: 10952828
N Engl J Med. 2000 Apr 13;342(15):1077-84
pubmed: 10760308
Anatol J Cardiol. 2015 Feb;15(2):143-8
pubmed: 25252299
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120